Vivus 9-28-98 updated/corrected medical info.
( correction pertains to the original Vivus study in the New England Jour of Med. as well as the introduction piece Re Sildenafil/Muse )
.As you go through the scientific evidence collected below, the
following are key points to remember:
SILDENAFIL/Viagra/Pfizer will ONLY work if there is SOME RESIDUAL HEALTHY penile tissue tha can produce some Nitric Oxide and cGMP.So
Sildenafil ONLY ENHANCES an ERECTION.So it will not work for the millions that have dead penile nerves and arteries such as the advanced diabetics;Muse instead works in diseased tissue veven that which does not produce Nitric Oxide or cGMP.
Thus Sildenefill and Muse are different and treat different stages of
impotence and different patients;and there are millions of them more
than enoough for each ( if Sildenef gets approved).
The best way is to use both.
Phentolamine is a non issue as Drs Morrales & Heaton from Queen's
University have commented in the below excellent review article on male
impotence.
Finally Brad there is a reason why Vivus got to 38 from 16 ( after
falling from 42 ), as a lot of investors will soon find out: there is
and there will be a giant demand for it.
-----------------------------------------------------------
MEDICAL REVIEW OF IMPOTENCE
collected by TA (gg)
Sildenafil/Viagra/Pfizer
traders.co.uk
Insulin Dependent Diabetes Trust Database
----------------------------------------------------------------
Alprostadil/Muse/Vivus
Treatment of men with erectile dysfunction with transurethral
alprostadil Padma Nathan H, Hellstrom WJG, Kuiser FE, Labasky, Tom Lue,Nolten,Norwood,Peterson, Shabsigh,Tam, V.Place,Gesudheit,and 90 other collaborators, for the MUSE study group.
New England Journal of Medicine 1997; 336: 1-7
(125-1000mgm) administered intra-urethrally in the office. Of these
996 men ( 65.9 % )had a erectile response satisfactory for intercourse and were subsequently entered into a placebo controlled double-blind trial: 461 received Alprostadil and 500 received placebo.Of the 461 receivig Alprostadil 299 had intercourse at least once( 64.9 % ), as compared to 93 of the 500 who received placebo ( 18.6 %, p<0.001 ) ). On average 7 of 10 men who received Alprostadil were followed by intercourse in men resposive to treatment.
The efficacy of Alprostadil was similar regardless of aga or the cause of erectile dysfunction, including vascular disease, diabetes, surgery and trauma ( p<0.001 for all comparisons with placebo ) .
10.8% of patients suffered from penile pain but this rarely resulted in discontinuing treatment. Hypotension occurred in the clinic in 3.3 % of men receiving Alprostadil.Hypotension- related symptoms were uncommon at home.No men had priapism or penile fibrosis.The response rates appear surprisingly good in patients with vasculogenic impotence.
( from the Departments of Urology of:
Univ of Southern California;The Mayo Clinic ; Tulane Univ Med Center;St Louis Univ;Univ of Utah;Univ of Calif;Univ of Wiconsin;Univ of Columbia, Columbia-Presbyterian Hospital;)
This is an important paper with large numbers of patients in a well
organised study.
-------------------------------------------------------------------
Alprostadil/Muse/Vivus after radical prostatectomy
pslgroup.com
-------------------------------------------------------------------
Alprostadil/Muse/ Vivus in Diabetics, one of the largest causes of
impotence:
vivus.com
-------------------------------------------------------------------
Review of Impotence
urol-int.org
-------------------------------------------------------------------
Sample of an Impotence Clinic literature.
peles.com
-------------------------------------------------------------------
Post by Dr BWLandes on Phentolamine/Vasomax/Zonagen, on it's EXTREMELY
DANGEROUS SIDE EFFECTS; NOT SAFE FOr HUMAN ORAL CONSUMPTION !! plus
assorted references on ERECTILE DYSFUNCTION; Everything you always
wanted to know but where afraid to ask:
www3.techstocks.com
--------------------------------------------------------------------
I |
